Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin.

Rosen DB, Harrington KH, Cordeiro JA, Leung LY, Putta S, Lacayo N, Laszlo GS, Gudgeon CJ, Hogge DE, Hawtin RE, Cesano A, Walter RB.

PLoS One. 2013;8(1):e53518. doi: 10.1371/journal.pone.0053518. Epub 2013 Jan 8.

2.

Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia.

Takeshita A.

Int J Hematol. 2013 Jun;97(6):703-16. doi: 10.1007/s12185-013-1365-1. Epub 2013 May 26. Review.

PMID:
23709007
3.
4.

Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin.

Cowan AJ, Laszlo GS, Estey EH, Walter RB.

Front Biosci (Landmark Ed). 2013 Jun 1;18:1311-34. Review.

5.

Targeting of CD34+CD38- cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in Acute Myeloid Leukaemia.

Jawad M, Yu N, Seedhouse C, Tandon K, Russell NH, Pallis M.

BMC Cancer. 2012 Sep 26;12:431. doi: 10.1186/1471-2407-12-431.

7.

The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells.

ten Cate B, Samplonius DF, Bijma T, de Leij LF, Helfrich W, Bremer E.

Leukemia. 2007 Feb;21(2):248-52. Epub 2006 Nov 23.

PMID:
17122863
8.

Deficient activation of Bak and Bax confers resistance to gemtuzumab ozogamicin-induced apoptotic cell death in AML.

Haag P, Viktorsson K, Lindberg ML, Kanter L, Lewensohn R, Stenke L.

Exp Hematol. 2009 Jun;37(6):755-66. doi: 10.1016/j.exphem.2009.03.002.

PMID:
19463775
9.

A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability.

ten Cate B, Bremer E, de Bruyn M, Bijma T, Samplonius D, Schwemmlein M, Huls G, Fey G, Helfrich W.

Leukemia. 2009 Aug;23(8):1389-97. doi: 10.1038/leu.2009.34. Epub 2009 Mar 5.

PMID:
19262596
10.

Gemtuzumab ozogamicin and olaparib exert synergistic cytotoxicity in CD33-positive HL-60 myeloid leukemia cells.

Yamauchi T, Uzui K, Nishi R, Shigemi H, Ueda T.

Anticancer Res. 2014 Oct;34(10):5487-94.

PMID:
25275045
11.
12.

In vitro experimental (211)At-anti-CD33 antibody therapy of leukaemia cells overcomes cellular resistance seen in vivo against gemtuzumab ozogamicin.

Petrich T, Korkmaz Z, Krull D, Frömke C, Meyer GJ, Knapp WH.

Eur J Nucl Med Mol Imaging. 2010 May;37(5):851-61. doi: 10.1007/s00259-009-1356-x. Epub 2010 Jan 27.

PMID:
20107790
13.

Targeted drug delivery by gemtuzumab ozogamicin: mechanism-based mathematical model for treatment strategy improvement and therapy individualization.

Jager E, van der Velden VH, te Marvelde JG, Walter RB, Agur Z, Vainstein V.

PLoS One. 2011;6(9):e24265. doi: 10.1371/journal.pone.0024265. Epub 2011 Sep 7.

14.

Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin.

Duong HK, Sekeres MA.

Clin Interv Aging. 2009;4:197-205. Epub 2009 May 14. Review.

16.

Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity.

Jedema I, Barge RM, van der Velden VH, Nijmeijer BA, van Dongen JJ, Willemze R, Falkenburg JH.

Leukemia. 2004 Feb;18(2):316-25.

PMID:
14614514
17.

CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy.

Walter RB, Gooley TA, van der Velden VH, Loken MR, van Dongen JJ, Flowers DA, Bernstein ID, Appelbaum FR.

Blood. 2007 May 15;109(10):4168-70. Epub 2007 Jan 16.

18.

Recent research and future prospects for gemtuzumab ozogamicin: could it make a comeback?

O'Hear C, Rubnitz JE.

Expert Rev Hematol. 2014 Aug;7(4):427-9. doi: 10.1586/17474086.2014.924849. Epub 2014 May 29.

PMID:
24871925
19.

Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers.

Matsui H, Takeshita A, Naito K, Shinjo K, Shigeno K, Maekawa M, Yamakawa Y, Tanimoto M, Kobayashi M, Ohnishi K, Ohno R.

Leukemia. 2002 May;16(5):813-9.

20.

Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3.

Amico D, Barbui AM, Erba E, Rambaldi A, Introna M, Golay J.

Blood. 2003 Jun 1;101(11):4589-97. Epub 2003 Feb 6.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk